SG11201509555UA - Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer - Google Patents
Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancerInfo
- Publication number
- SG11201509555UA SG11201509555UA SG11201509555UA SG11201509555UA SG11201509555UA SG 11201509555U A SG11201509555U A SG 11201509555UA SG 11201509555U A SG11201509555U A SG 11201509555UA SG 11201509555U A SG11201509555U A SG 11201509555UA SG 11201509555U A SG11201509555U A SG 11201509555UA
- Authority
- SG
- Singapore
- Prior art keywords
- dihydroquercetin
- metformin
- cancer
- treatment
- pharmaceutical combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013110278 | 2013-05-24 | ||
| PCT/JP2014/064354 WO2014189152A1 (en) | 2013-05-24 | 2014-05-23 | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509555UA true SG11201509555UA (en) | 2015-12-30 |
Family
ID=50980347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509555UA SG11201509555UA (en) | 2013-05-24 | 2014-05-23 | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9808440B2 (en) |
| EP (1) | EP3003296B1 (en) |
| JP (2) | JP6440212B2 (en) |
| KR (1) | KR102182946B1 (en) |
| CN (1) | CN105263484B (en) |
| AR (1) | AR096402A1 (en) |
| AU (1) | AU2014269401A1 (en) |
| CA (1) | CA2912881A1 (en) |
| HK (1) | HK1223304A1 (en) |
| PH (1) | PH12015502616A1 (en) |
| RU (2) | RU2671488C2 (en) |
| SG (1) | SG11201509555UA (en) |
| TW (2) | TWI688387B (en) |
| WO (1) | WO2014189152A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10468144B2 (en) | 2014-08-19 | 2019-11-05 | Nuscale Power, Llc | Spent fuel storage rack |
| CN105330575A (en) * | 2015-10-14 | 2016-02-17 | 吉林海格力斯医药生物科技发展有限公司 | Compound for treating bone marrow injury caused by radiotherapy and chemotherapy |
| US11185516B2 (en) | 2016-09-30 | 2021-11-30 | Laboratorios Silanes S.A. De C.V. | Metformin glycinate, pharmaceutical compositions comprising the same, and methods of using the same |
| CN108078938A (en) * | 2018-01-15 | 2018-05-29 | 栾晓民 | A kind of preparation method and application of dihydroquercetin preparation |
| WO2020033019A2 (en) | 2018-04-25 | 2020-02-13 | Charles R. Drew University Of Medicine And Science | Novel mct4 inhibitors and uses thereof |
| KR102349477B1 (en) * | 2019-08-30 | 2022-01-10 | (주)프론트바이오 | Pharmaceutical composition for preventing or treating cancer comprising biguanides, and flavone, hydroxyflavone, flvanone, flavone derivatives, hydroxyflavone derivatives, flavanone derivatives as active ingredients |
| MX2022010214A (en) * | 2020-02-25 | 2022-10-07 | Otsuka Pharma Co Ltd | Combination decitabine and cedazuridine solid oral dosage forms. |
| CN111467332B (en) * | 2020-03-31 | 2021-08-24 | 中国科学院苏州生物医学工程技术研究所 | Application of low-temperature plasma and metformin in combination |
| RU2740946C1 (en) * | 2020-06-30 | 2021-01-21 | Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) | Agent for reducing pathological changes in prostatic hyperplasia |
| US20220409567A1 (en) * | 2021-06-23 | 2022-12-29 | Thomas Winston | Adjuvant and complementary therapies for the treatment of cancer |
| CN115154458B (en) * | 2022-07-25 | 2023-11-10 | 天水师范学院 | Preparation method of quercetin-metformin hydrochloride compound hypoglycemic drug |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3523287B2 (en) * | 1993-02-26 | 2004-04-26 | 丸善製薬株式会社 | Carcinogenesis promotion inhibitor |
| US8178123B2 (en) | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| CN1320925C (en) * | 2005-03-30 | 2007-06-13 | 淮北市辉克药业有限公司 | Long time use compound preparation for treating diabetes |
| CA2606658A1 (en) | 2006-10-13 | 2008-04-13 | Mike Tyers | Compositions and methods for treating neurological disorders or damage |
| DE102008029460A1 (en) | 2008-06-20 | 2009-12-31 | Otkrytoe Aktsionernoe Obschestvo Zavod Ekologicheskoy Tekhniki I Ekopitaniya 'diod' | Taxifoline derivatives for the prophylaxis and treatment of neurological and psychiatric disorders of the central nervous system |
| JP2012505251A (en) | 2008-10-10 | 2012-03-01 | リメリック バイオファーマ， インコーポレイテッド | Pyrone for the treatment of metabolic diseases |
| JP2013503171A (en) * | 2009-08-25 | 2013-01-31 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Use of metformin in the treatment and prevention of cancer |
| WO2012122295A2 (en) * | 2011-03-07 | 2012-09-13 | Ned Biosystems, Inc. | Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin |
| RU2451506C1 (en) * | 2011-06-02 | 2012-05-27 | Сергей Юрьевич Лешков | Combination for treatment of diabetes and complications thereof |
| JP5645796B2 (en) | 2011-11-21 | 2014-12-24 | 東京エレクトロン株式会社 | Liquid processing apparatus and liquid processing method |
-
2014
- 2014-05-23 US US14/893,127 patent/US9808440B2/en active Active
- 2014-05-23 KR KR1020157036511A patent/KR102182946B1/en active IP Right Grant
- 2014-05-23 TW TW107136794A patent/TWI688387B/en active
- 2014-05-23 WO PCT/JP2014/064354 patent/WO2014189152A1/en active Application Filing
- 2014-05-23 RU RU2015155283A patent/RU2671488C2/en active
- 2014-05-23 CA CA2912881A patent/CA2912881A1/en not_active Abandoned
- 2014-05-23 RU RU2018135973A patent/RU2018135973A/en unknown
- 2014-05-23 EP EP14732025.3A patent/EP3003296B1/en active Active
- 2014-05-23 JP JP2016514679A patent/JP6440212B2/en active Active
- 2014-05-23 AR ARP140102045A patent/AR096402A1/en unknown
- 2014-05-23 TW TW103118093A patent/TWI667021B/en active
- 2014-05-23 AU AU2014269401A patent/AU2014269401A1/en not_active Abandoned
- 2014-05-23 SG SG11201509555UA patent/SG11201509555UA/en unknown
- 2014-05-23 CN CN201480028924.0A patent/CN105263484B/en active Active
-
2015
- 2015-11-24 PH PH12015502616A patent/PH12015502616A1/en unknown
-
2016
- 2016-10-11 HK HK16111724.2A patent/HK1223304A1/en unknown
-
2017
- 2017-10-03 US US15/723,369 patent/US10292962B2/en active Active
- 2017-10-03 US US15/723,377 patent/US20180036280A1/en not_active Abandoned
-
2018
- 2018-08-21 US US16/106,121 patent/US20180353466A1/en not_active Abandoned
- 2018-11-15 JP JP2018214368A patent/JP6754071B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AR096402A1 (en) | 2015-12-30 |
| EP3003296A1 (en) | 2016-04-13 |
| RU2018135973A (en) | 2018-11-14 |
| RU2015155283A (en) | 2017-06-29 |
| EP3003296B1 (en) | 2018-10-10 |
| WO2014189152A1 (en) | 2014-11-27 |
| US20180036280A1 (en) | 2018-02-08 |
| US20160101082A1 (en) | 2016-04-14 |
| CA2912881A1 (en) | 2014-11-27 |
| CN105263484A (en) | 2016-01-20 |
| JP6754071B2 (en) | 2020-09-09 |
| TW201906603A (en) | 2019-02-16 |
| KR102182946B1 (en) | 2020-11-25 |
| TW201536275A (en) | 2015-10-01 |
| RU2671488C2 (en) | 2018-11-01 |
| AU2014269401A1 (en) | 2016-01-21 |
| JP6440212B2 (en) | 2018-12-19 |
| TWI667021B (en) | 2019-08-01 |
| US20180050014A1 (en) | 2018-02-22 |
| US10292962B2 (en) | 2019-05-21 |
| PH12015502616A1 (en) | 2016-02-29 |
| TWI688387B (en) | 2020-03-21 |
| JP2016522202A (en) | 2016-07-28 |
| CN105263484B (en) | 2018-08-03 |
| HK1223304A1 (en) | 2017-07-28 |
| US9808440B2 (en) | 2017-11-07 |
| KR20160013164A (en) | 2016-02-03 |
| US20180353466A1 (en) | 2018-12-13 |
| RU2018135973A3 (en) | 2022-03-04 |
| JP2019048850A (en) | 2019-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282741A (en) | Tazemetostat in combination with a standard care agent for use in the treatment of cancer | |
| HK1223304A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| PL3031826T3 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
| PT3033086T (en) | Combination therapy for the treatment of cancer | |
| HK1221178A1 (en) | Cabozantinib dosage form and use in the treatment of cancer | |
| IL242386B (en) | Use of eribulin and lenvatinib as combination therapy for treatment of cancer | |
| GB201320729D0 (en) | Therapeutic compounds and their use | |
| IL242483B (en) | Omomyc compositions and the use thereof for the treatment of cancer | |
| GB201411465D0 (en) | Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer | |
| IL251816B (en) | A pharmaceutical combination comprising alvocidib and bromodomain (brd) inhibitor for use in the treatment of cancer | |
| IL258854A (en) | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer | |
| PL3089749T3 (en) | Combined preparations for the treatment of cancer | |
| HK1222548A1 (en) | Pharmaceutical combinations for the treatment of cancer | |
| IL247586A0 (en) | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer | |
| EP2962693A4 (en) | Pharmaceutical composition for prevention and/or treatment of cancer | |
| GB201311361D0 (en) | Compounds and their therapeutic use | |
| GB201308736D0 (en) | Compounds and their therapeutic use | |
| IL245998B (en) | Pharmaceutical compositions for use in the treatment and prevention of metastatic cancer | |
| PL3016948T3 (en) | 2-acylaminothiazoles for the treatment of cancer | |
| TWI561255B (en) | Use of umirolimus and its derivatives for treating cancer | |
| HUP1300454A2 (en) | Pharmaceutical compositions for the treatment and prevention of tumorous diseases | |
| GB201317373D0 (en) | Treatment and prevention of cancer | |
| AU2013904239A0 (en) | Pharmaceutical combinations for the treatment of cancer | |
| GB201317804D0 (en) | Therapeutic compounds and their use |